These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11237378)

  • 1. 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer.
    Jodrell DI; Stewart M; Aird R; Knowles G; Bowman A; Wall L; McLean C
    Br J Cancer; 2001 Mar; 84(5):600-3. PubMed ID: 11237378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
    Chau I; Webb A; Cunningham D; Hill M; Waters JS; Norman A; Massey A
    Br J Cancer; 2001 Nov; 85(9):1258-64. PubMed ID: 11720458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
    Ychou M; Duffour J; Kramar A; Debrigode C; Gourgou S; Bressolle F; Pinguet F
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):282-90. PubMed ID: 12827293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
    Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer.
    Chau I; Norman AR; Cunningham D; Iveson T; Hill M; Hickish T; Lofts F; Jodrell D; Webb A; Tait D; Ross PJ; Shellito P; Oates JR
    Eur J Cancer; 2005 Jul; 41(11):1551-9. PubMed ID: 16026692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-FU split dose; a phase I/II and pharmacokinetic study of a different schedule of the Nordic regimen in advanced colorectal carcinoma.
    Berglund A; Carlsson G; Gustavsson B; Frödin JE; Ragnhammar P; Glimelius B
    Anticancer Res; 2003; 23(2C):1789-94. PubMed ID: 12820460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
    Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of pharmacokinetic interaction between 5-fluorouracil and oxaliplatin.
    Joel SP; Papamichael D; Richards F; Davis T; Aslanis V; Chatelut E; Locke K; Slevin ML; Seymour MT
    Clin Pharmacol Ther; 2004 Jul; 76(1):45-54. PubMed ID: 15229463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of bolus 5-fluorouracil: relationship between dose, plasma concentrations, area-under-the-curve and toxicity.
    Codacci-Pisanelli G; Pinedo HM; Lankelma J; Van Groeningen CJ; Van Kuilenburg AB; Van Gennip AH; Peters GJ
    J Chemother; 2005 Jun; 17(3):315-20. PubMed ID: 16038526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Puzzles in the clinical pharmacokinetics of fluorouracil.
    Desoize B; Bouche O; Berthiot G; Coninx P
    Anticancer Res; 1998; 18(6B):4607-10. PubMed ID: 9891526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-interferon does not increase the efficacy of 5-fluorouracil in advanced colorectal cancer.
    Thirion P; Piedbois P; Buyse M; O'Dwyer PJ; Cunningham D; Man A; Greco FA; Colucci G; Köhne CH; Di Constanzo F; Piga A; Palmeri S; Dufour P; Cassano A; Pajkos G; Pensel RA; Aykan NF; Marsh J; Seymour MT;
    Br J Cancer; 2001 Mar; 84(5):611-20. PubMed ID: 11237380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity and toxicity of oxaliplatin and bolus fluorouracil plus leucovorin in pretreated colorectal cancer patients: a phase II study.
    Ferraresi V; Giampaolo MA; Gabriele A; Mansueto G; Buccilli A; Giannarelli D; Ciccarese M; Gamucci T
    J Exp Clin Cancer Res; 2005 Jun; 24(2):187-96. PubMed ID: 16110750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
    J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of two fluorouracil administration regimens for colorectal cancer.
    Matsusaka S; Yamasaki H; Kitayama Y; Okada T; Maeda S
    Oncol Rep; 2003; 10(1):109-13. PubMed ID: 12469154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
    Sobrero A; Guglielmi A; Cirillo M; Recaldin E; Frassineti GL; Aschele C; Ravaioli A; Testore P; Caroti C; Gallo L; Pessi MA; Cortesi E; Turci D; Grossi F; Labianca R
    Br J Cancer; 2001 Apr; 84(8):1023-8. PubMed ID: 11308248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic drug monitoring of 5-fluorouracil after its administration in high-dose protocols].
    Boisdron-Celle M; Le Guellec C;
    Therapie; 2010; 65(3):171-6. PubMed ID: 20699067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose and time dependencies of 5-fluorouracil pharmacokinetics.
    Terret C; Erdociain E; Guimbaud R; Boisdron-Celle M; McLeod HL; Féty-Deporte R; Lafont T; Gamelin E; Bugat R; Canal P; Chatelut E
    Clin Pharmacol Ther; 2000 Sep; 68(3):270-9. PubMed ID: 11014408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Concentrations of 5-fluorouracil (5-FU) in serum and tissues at venous injection of tegafur or 5-FU--clinical study on colorectal cancer].
    Kojima T; Suzumura K; Kanemitsu T; Miyashita A; Inamura Y; Owa Y; Naruse T
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):547-51. PubMed ID: 9530361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.